Pay in 4 interest-free payments of $6.36 Learn more
Ships within 48 hours · Estimated delivery Sep 16 - Sep 21
health canada semaglutide approves Ozempic® to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease GLP-1 - ELIVATE DRIP Offer_TIMELESS30 Size and Gauge:31 Gauge, 1 cc, 1/4" Inch (6mm)
GLP-1 - ELIVATE DRIP SPA
In a long-term cardio-renal outcome trial [see Clinical Studies 14.5], in patients with chronic kidney disease, the occurrence of lower limb amputations was reported with event rates of 2.9, and 4.3 events per 1,000 patient-years in the placebo, and JARDIANCE 10 mg treatment arms, respectively
Offer_TIMELESS30
Size and Gauge:31 Gauge, 1 cc, 1/4" Inch (6mm)
Farxiga/Forxiga (dapagliflozin) Disease area(s): Metabolic diseases Manufacturer(s): AstraZeneca 2024 Sales (USD): $7.72 billion Why it sold so well: In 2024, AstraZeneca’s Farxiga achieved robust sales growth, with revenues increasing by 21% year-over-year to $1.9 billion in the fourth quarter alone and by 28% compared to 2023, making it the company’s top seller in 2024
US$ 23.63
US$ 22.39
US$ 21.57
US$ 28.54
US$ 21.64
US$ 25.10
